Cargando…

A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri

Frog skin secretions contain complex peptidomes and peptidic protease inhibitors that are one of the biologically and structurally described groups of components. In the present study, by use of molecular ‘shotgun’ cloning and LC MS/MS fractionation sequencing, a novel Bowman–Birk-type heptadecapept...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yuxin, Long, Qilin, Xu, Ying, Guo, Shaodong, Chen, Tianbao, Wang, Lei, Zhou, Mei, Zhang, Yingqi, Shaw, Chris, Walker, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408667/
https://www.ncbi.nlm.nih.gov/pubmed/28356487
http://dx.doi.org/10.1042/BSR20160593
_version_ 1783232343013588992
author Wu, Yuxin
Long, Qilin
Xu, Ying
Guo, Shaodong
Chen, Tianbao
Wang, Lei
Zhou, Mei
Zhang, Yingqi
Shaw, Chris
Walker, Brian
author_facet Wu, Yuxin
Long, Qilin
Xu, Ying
Guo, Shaodong
Chen, Tianbao
Wang, Lei
Zhou, Mei
Zhang, Yingqi
Shaw, Chris
Walker, Brian
author_sort Wu, Yuxin
collection PubMed
description Frog skin secretions contain complex peptidomes and peptidic protease inhibitors that are one of the biologically and structurally described groups of components. In the present study, by use of molecular ‘shotgun’ cloning and LC MS/MS fractionation sequencing, a novel Bowman–Birk-type heptadecapeptide (AALKGCWTKSIPPKPCF-amide), named Odorrana schmackeri Trypsin Inhibitor (OSTI), with a canonical Cys(6)–Cys(16) disulfide bridge, was isolated and identified in piebald odorous frog (O. schmackeri) skin secretion. A synthetic replicate of OSTI-exhibited trypsin inhibitory activity with a K(i) value of 0.3 ± 0.04 nM and also a tryptase inhibitory effect with a K(i) of 2.5 ± 0.6 μM. This is the first time that this property has been reported for a peptide originating from amphibian sources. In addition, substituting lysine (K) with phenylalanine (F) at the presumed P1 position, completely abrogated the trypsin and tryptase inhibition, but produced a strong chymotrypsin inhibition with a K(i) of 1.0 ± 0.1 μM. Thus, the specificity of this peptidic protease inhibitor could be optimized through modifying the amino acid residue at the presumed P1 position and this novel native OSTI, along with its analogue, [Phe(9)]-OSTI, have expanded the potential drug discovery and development pipeline directed towards alleviation of serine protease-mediated pathologies.
format Online
Article
Text
id pubmed-5408667
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-54086672017-05-04 A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri Wu, Yuxin Long, Qilin Xu, Ying Guo, Shaodong Chen, Tianbao Wang, Lei Zhou, Mei Zhang, Yingqi Shaw, Chris Walker, Brian Biosci Rep Research Articles Frog skin secretions contain complex peptidomes and peptidic protease inhibitors that are one of the biologically and structurally described groups of components. In the present study, by use of molecular ‘shotgun’ cloning and LC MS/MS fractionation sequencing, a novel Bowman–Birk-type heptadecapeptide (AALKGCWTKSIPPKPCF-amide), named Odorrana schmackeri Trypsin Inhibitor (OSTI), with a canonical Cys(6)–Cys(16) disulfide bridge, was isolated and identified in piebald odorous frog (O. schmackeri) skin secretion. A synthetic replicate of OSTI-exhibited trypsin inhibitory activity with a K(i) value of 0.3 ± 0.04 nM and also a tryptase inhibitory effect with a K(i) of 2.5 ± 0.6 μM. This is the first time that this property has been reported for a peptide originating from amphibian sources. In addition, substituting lysine (K) with phenylalanine (F) at the presumed P1 position, completely abrogated the trypsin and tryptase inhibition, but produced a strong chymotrypsin inhibition with a K(i) of 1.0 ± 0.1 μM. Thus, the specificity of this peptidic protease inhibitor could be optimized through modifying the amino acid residue at the presumed P1 position and this novel native OSTI, along with its analogue, [Phe(9)]-OSTI, have expanded the potential drug discovery and development pipeline directed towards alleviation of serine protease-mediated pathologies. Portland Press Ltd. 2017-04-28 /pmc/articles/PMC5408667/ /pubmed/28356487 http://dx.doi.org/10.1042/BSR20160593 Text en © 2017 The Author(s). http://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Articles
Wu, Yuxin
Long, Qilin
Xu, Ying
Guo, Shaodong
Chen, Tianbao
Wang, Lei
Zhou, Mei
Zhang, Yingqi
Shaw, Chris
Walker, Brian
A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri
title A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri
title_full A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri
title_fullStr A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri
title_full_unstemmed A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri
title_short A structural and functional analogue of a Bowman–Birk-type protease inhibitor from Odorrana schmackeri
title_sort structural and functional analogue of a bowman–birk-type protease inhibitor from odorrana schmackeri
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408667/
https://www.ncbi.nlm.nih.gov/pubmed/28356487
http://dx.doi.org/10.1042/BSR20160593
work_keys_str_mv AT wuyuxin astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT longqilin astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT xuying astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT guoshaodong astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT chentianbao astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT wanglei astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT zhoumei astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT zhangyingqi astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT shawchris astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT walkerbrian astructuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT wuyuxin structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT longqilin structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT xuying structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT guoshaodong structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT chentianbao structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT wanglei structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT zhoumei structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT zhangyingqi structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT shawchris structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri
AT walkerbrian structuralandfunctionalanalogueofabowmanbirktypeproteaseinhibitorfromodorranaschmackeri